（编辑 姚尧） 证券日报网讯 10月20日晚间，爱建集团发布公告称，公司于2025年10月20日接公司控股股东——上海 均瑶（集团）有限公司《关于股份质押情况的告知函》，获悉其将所持有本公司的部分股份办理了质押 手续。本次质押股数3，591万股。 ...

截至本公告日，上海爱建集团股份有限公司（以下简称"爱建集团"、"公 司"或"本公司"）控股股东上海均瑶（集团）有限公司（以下简称"均瑶集团"） 持有本公司股份 483,333,355 股，占公司总股本的比例为 30.34%。均瑶集团本 次质押股份数量 35,910,000 股，本次质押后，均瑶集团持有公司股份累计质押 数量 381,973,981 股，占其所持公司股份的 79.03%，占公司总股本的 23.98%。 公司于 2025 年 10 月 20 日接公司控股股东——上海均瑶（集团）有限公司 《关于股份质押情况的告知函》（以下简称"告知函"），获悉其将所持有本公司 的部分股份办理了质押手续，具体情况如下： 证券代码：600643 证券简称：爱建集团 公告编号：临 2025-045 上海爱建集团股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 障用途。 3、控股股东累计质押股份情况 截至公告披露日，公司控股股东累计质押股份情况如下: 二、控股股东股份质押情况 ...

Core Viewpoint - The diversified financial sector experienced a decline of 0.95% on September 30, with COFCO Capital leading the drop, while the Shanghai Composite Index rose by 0.52% and the Shenzhen Component Index increased by 0.35% [1] Group 1: Market Performance - The diversified financial sector's stocks showed mixed performance, with notable gainers including Ruida Futures (up 3.06%) and ST Rendong (up 2.89%), while several stocks like ST Xiongmao and ST Rendong faced declines [1][2] - The trading volume for Ruida Futures reached 77,600 lots, with a transaction value of approximately 166 million yuan [1] Group 2: Capital Flow - The diversified financial sector saw a net outflow of 570 million yuan from major funds, while retail investors contributed a net inflow of 464 million yuan [2] - The capital flow data indicates that stocks like Haide Co. and ST Xiongmao experienced significant net inflows from retail investors, despite overall negative trends in major and speculative funds [3]

截至本公告日，上海爱建集团股份有限公司（以下简称"爱建集团"、"公 司"或"本公司"）控股股东上海均瑶（集团）有限公司（以下简称"均瑶集团"） 持有本公司股份 483,333,355 股，占公司总股本的比例为 30.34%。均瑶集团本 次质押股份数量 12,000,000 股，本次质押后，均瑶集团持有公司股份累计质押 数量 346,063,981 股，占其所持公司股份的 71.60%，占公司总股本的 21.72%。 公司于 2025 年 9 月 29 日接公司控股股东——上海均瑶（集团）有限公司《关 于股份质押情况的告知函》（以下简称"告知函"），获悉其将所持有本公司的部 分股份办理了质押手续，具体情况如下： 一、本次股份质押具体情况 证券代码：600643 证券简称：爱建集团 公告编号：临 2025-044 上海爱建集团股份有限公司 关于控股股东部分股份质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示: 截至公告披露日，公司控股股东累计质押股份情况如下: 1、本次股份质押基本情况 | | | | ...

Core Viewpoint - Aijian Group's stock has shown a mixed performance in recent trading, with a year-to-date increase of 10.06% but a decline in the last 60 days of 14.82% [1][2] Group 1: Stock Performance - On September 29, Aijian Group's stock rose by 2.15%, reaching 5.69 CNY per share, with a trading volume of 70.72 million CNY and a turnover rate of 0.80% [1] - The company has experienced a net outflow of 2.26 million CNY in principal funds, with significant selling pressure observed [1] - Year-to-date, the stock has been on the龙虎榜 four times, with the most recent instance on July 2, where it recorded a net buy of -39.32 million CNY [1] Group 2: Company Overview - Aijian Group, established on November 28, 1983, and listed on April 26, 1993, is based in Shanghai and operates in various financial services including trust, leasing, asset management, and private equity investment [2] - The company's revenue composition includes leasing business (53.03%), product sales (32.31%), management and consulting services (8.70%), and property management (3.26%) [2] - As of June 30, 2025, Aijian Group had 101,500 shareholders, an increase of 76.39% from the previous period, with an average of 15,665 circulating shares per shareholder, down 43.31% [2] Group 3: Financial Performance - For the first half of 2025, Aijian Group reported a revenue of 1.08 billion CNY, a year-on-year decrease of 15.20%, and a net profit attributable to shareholders of 140 million CNY, down 33.26% [2] - The company has distributed a total of 2.39 billion CNY in dividends since its A-share listing, with 177 million CNY distributed over the last three years [3] - As of June 30, 2025, the largest circulating shareholder is Hong Kong Central Clearing Limited, holding 23.61 million shares, a decrease of 128,800 shares from the previous period [3]

Core Viewpoint - Jianyuan Trust announced abnormal fluctuations in stock trading, highlighting ongoing operational risks while actively managing existing risk assets and expanding business operations [1] Group 1: Legal Risks - The company faces significant litigation risks due to prior trust business commitments made since 2019, resulting in numerous lawsuits. Currently, there are three ongoing cases with a total principal amount involved of 792 million yuan [1] - The company is committed to addressing and mitigating these litigation risks, although they remain a concern [1] Group 2: Trust Business Risks - As of June 30, 2025, the company manages a total trust scale of 337.89 billion yuan. Among these, 173 trust projects have matured, leaving a remaining trust business scale of 116.24 billion yuan [1] - The complexity and scale of the remaining trust business, combined with macroeconomic factors, pose significant challenges for asset disposal [1]

Group 1 - The core viewpoint of the article highlights the resurgence of low-priced stocks, with specific companies such as Shanzi Gaoke, Jingxing Paper, Jianyuan Trust, Hangdian Co., and Baili Technology reaching their daily price limits [1] Group 2 - The article notes that the performance of low-priced stocks has shown a significant increase, indicating a potential trend in the market [1]

Group 1 - The AiTech Forum focused on providing a clear pathway for Chinese pharmaceutical companies to expand internationally, with insights from global institutions and industry representatives [1][2] - Ireland is positioned as a regulatory hub for the EU, offering compliance guidance and local infrastructure support to assist Chinese pharmaceutical companies in entering the European market [1] - The International Drug Information Association (DIA) aims to facilitate deep cooperation among global regulatory bodies and support Chinese innovative drug companies in establishing a "dual circulation" model for international market access [1][2] Group 2 - The "three-tier service system" for technology transfer includes demand-side connections with hospitals and large enterprises, supply-side integration of university innovations, and service-side support for IP rights and global resource networks [2] - Local innovative pharmaceutical companies shared their strategies for international expansion, emphasizing the importance of product strength and market timing [2] - Companies are prioritizing emerging markets for vaccine registration and sales, while also developing new vaccine technologies [2] Group 3 - China is becoming a significant source of innovative drugs for multinational pharmaceutical companies, with advantages in regulatory alignment, cost efficiency, and innovation capabilities [3] - A strategic cooperation signing ceremony was held to create a platform for ongoing collaboration among government, enterprises, international institutions, and financial capital [3] - The goal is to accelerate the globalization of China's innovative drug industry and inject new momentum into the high-quality development of the biopharmaceutical sector [3]

Group 1 - The company will hold a half-year performance briefing on September 23, 2025, from 15:00 to 16:00 [2][4] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [3][4] - Investors can submit questions from September 16 to September 22, 2025, and the company will address common concerns during the briefing [2][5] Group 2 - Key personnel attending the briefing include the company's president, vice president, financial director, and independent directors [4] - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center website [5] - After the briefing, the main content and details will be available for review on the Shanghai Stock Exchange Roadshow Center [6]

证券代码：600643 证券简称：爱建集团 公告编号：临 2025-043 上海爱建集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 （ 三 ） 会 议 召 开 地 址 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 ， 网 址 为 ： https://roadshow.sseinfo.com/ 重要内容提示: 上海爱建集团股份有限公司已于 2025 年 8 月 23 日在上海证券交易所网站 （www.sse.com.cn）披露本公司 2025 年半年度报告。为便于广大投资者更全面 深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 9 月 23 日下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进 行交流。 一、业绩说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2025 年半年度的经营成 果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关 ...